Home » Clinical Trials » Solid tumors » NCT06820424
NCT06820424

A Phase I Clinical Study to Evaluate the Safety and Preliminary Efficacy of CDH17 CAR-T in Patients with CDH17-positive Advanced Solid Tumors

Study Summary

This is a single-center, open-label, single-arm study to evaluate the safety and preliminary efficacy of anti-CDH17 CAR-T cells in patients with CDH17-positive advanced solid tumors.

Want to learn more about this trial?

Request More Info

Interventions

Anti-CDH17 CAR-T cells infusionBIOLOGICAL
Subiects who meet the enrollment conditions will receive intravenous infusion of anti-CDH17 CAR-T Cells after lymphodepleting therapy.

Study Locations

FacilityCityStateCountry
Sanbin WangKunmingYunnanChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026